Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity

Phase 1

Active, not recruiting

Conditions: Obesity
Overweight

Interventions: Drug: Survodutide
Drug: Bupropion
Drug: Caffeine
Drug: Midazolam

First Posted Date: 2024-08-21

Last Posted Date: 2024-12-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT06564441

Locations: 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium

A Study to Test Different Doses of BI 1569912 in People With Depression

Phase 2

Recruiting

Conditions: Depressive Disorder, Major

Interventions: Drug: BI 1569912
Drug: Placebo matching BI 1569912

First Posted Date: 2024-08-16

Last Posted Date: 2024-12-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 222

Registration Number: NCT06558344

Locations: 🇺🇸
Excell Research Inc., Oceanside, California, United States
🇺🇸
Artemis Institute for Clinical Research, LLC, San Diego, California, United States
🇺🇸
Advanced Discovery Research LLC, Atlanta, Georgia, United States

and more 39 locations

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

Phase 3

Recruiting

Conditions: Kidney Disease, Chronic

Interventions: Drug: Placebo matching BI 690517
Drug: BI 690517
Drug: Empagliflozin

First Posted Date: 2024-08-01

Last Posted Date: 2024-12-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 11000

Registration Number: NCT06531824

Locations: 🇺🇸
Texas Institute for Kidney and Endocrine Disorders, Lufkin, Texas, United States
🇩🇪
Universitätsklinikum Würzburg AÖR, Würzburg, Germany
🇬🇧
Churchill Hospital, Oxford, United Kingdom

Post Marketing Surveillance of JARDIANCE in Chronic Kidney Disease

Recruiting

Conditions: Kidney Disease, Chronic

Interventions: Drug: JARDIANCE®

First Posted Date: 2024-07-30

Last Posted Date: 2024-11-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1000

Registration Number: NCT06527846

Locations: 🇯🇵
Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan

A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy

Phase 1

Recruiting

Conditions: Pancreatic Ductal Adenocarcinoma

Interventions: Drug: BI 765883
Drug: gemcitabine
Drug: nab-paclitaxel

First Posted Date: 2024-07-30

Last Posted Date: 2024-11-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 68

Registration Number: NCT06528093

Locations: 🇧🇪
Brussels - UNIV Saint-Luc, Bruxelles, Belgium
🇧🇪
UZ Leuven, Leuven, Belgium
🇫🇷
CTR Leon Berard, Lyon, France

and more 11 locations

A Study to Test How Well Healthy People Tolerate Spesolimab When Given in 2 Different Ways

Phase 1

Active, not recruiting

Conditions: Healthy

Interventions: Drug: Spesolimab

First Posted Date: 2024-07-25

Last Posted Date: 2024-12-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 60

Registration Number: NCT06520514

Locations: 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium

A Study in Healthy Men to Test How BI 1569912 is Processed in the Body

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1569912 (C-14)
Drug: BI 1569912 (C-13)

First Posted Date: 2024-07-25

Last Posted Date: 2024-11-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 8

Registration Number: NCT06520553

Locations: 🇳🇱
ICON-Groningen-62040, Groningen, Netherlands

A Study to Test How Well BI 3720931 is Tolerated and Whether it Improves Lung Function in People With Cystic Fibrosis (Lenticlair™ 1)

Phase 1

Recruiting

Conditions: Cystic Fibrosis

Interventions: Genetic: BI 3720931
Drug: Placebo
Device: Inhaler

First Posted Date: 2024-07-23

Last Posted Date: 2024-12-02

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT06515002

Locations: 🇫🇷
HOP Gui de Chauliac, Montpellier, France
🇫🇷
HOP Necker, Paris, France
🇮🇹
Istituto G. Gaslini, Genova, Italy

and more 6 locations

A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Zongertinib
Drug: Dabigatran-etexilate
Drug: Rosuvastatin
Drug: Metformin hydrochloride
Drug: Furosemide

First Posted Date: 2024-07-17

Last Posted Date: 2024-12-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 32

Registration Number: NCT06504862

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study in Healthy Men to Test Whether Zongertinib Affects How 3 Other Medicines (Midazolam, Omeprazole, and Repaglinide) Are Taken up and Processed by the Body

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: zongertinib
Drug: midazolam
Drug: omeprazole
Drug: repaglinide

First Posted Date: 2024-07-10

Last Posted Date: 2024-11-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT06494761

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy